Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy:...

Area of Science:

• Cardiology
• Clinical Medicine
• Interventional Cardiology

Background:

• Patients experiencing re-infarction during hospitalization for ST-elevation myocardial infarction (STEMI) have poorer survival rates.
• Understanding and optimizing the treatment of re-infarction is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the utilization of reperfusion therapies within 12 hours of re-infarction.
• To determine if reperfusion therapy use is associated with 30-day mortality in STEMI patients with re-infarction.

Main Methods:

• Analysis of 552 patients with re-infarction from the HERO-2 trial (17,073 STEMI patients).
• Examined reperfusion therapy (fibrinolysis, PCI) utilization and its association with 30-day mortality across different global regions.
• Utilized Cox regression analysis to adjust for clinical variables and treatment assignment.

Main Results:

• Re-infarction occurred in 2.8% (bivalirudin) and 3.6% (heparin) of patients; treatment assignment did not affect re-infarction mortality.
• Patients with re-infarction had significantly higher 30-day mortality (24%) compared to those without (10%).
• Reperfusion therapy (fibrinolysis or PCI) for re-infarction was associated with lower 30-day mortality (15% vs. 27%) and PCI showed a significant mortality reduction (HR 0.18).

Conclusions:

• Reperfusion therapies for re-infarction are significantly under-utilized, especially in non-Western countries.
• Percutaneous coronary intervention (PCI) for re-infarction is linked to reduced 30-day mortality, potentially due to patient selection and treatment efficacy.
• Regional variations in treatment utilization and outcomes highlight disparities in care for STEMI patients with re-infarction.